Freelite™ Serum Free Light Chain Assays
This site is for Healthcare Professionals only
Click here for Patient Information
Latest News Headlines
Freelite is a major breakthrough for the detection and monitoring of Multiple Myeloma (MM) and other B-cell dyscrasia. There is now significant clinical evidence indicating the benefit of serum free light chain assays in initial screening for monoclonal gammopathies, identifying AL amyloidosis and Nonsecretory MM patients missed by conventional electrophoretic methods, for risk stratification of MGUS patients * and rapid evaluation of treatment efficacy.
Freelite assays were developed by The Binding Site to measure free lambda and free kappa immunoglobulin light chains. Our expertise in the manufacture of antibodies has enabled us to provide a quantifiable, highly specific, automatable free light chain assay for serum.
Review the clinical evidence for the utility of Freelite in detecting and monitoring plasma cell disorders and compare the results from laboratory protocols with and without Freelite.
* In the USA diagnostic use of this product is restricted to those stated in the product insert
Latest News 18 March 2008
New Cystatin C assay for Roche Modular P
Binding Site's new assay for the quantitation of cystatin C in human serum or plasma shows excellent precision and linearity, and is easily installed on the Roche P Module.
The assay utilises calibrators and controls which are manufactured from human serum.
A recent publication (Flodin, M. et al) highlights the importance of using calibrators and controls that do not differ from patient samples, and the use of recombinant Cystatin C in other commercial assays has also proved to be problematic when measuring patient samples (Mojiminiyi, O.A. et al). More
